Navigating the complex landscape of GLP-1 receptor agonists: Barriers, opportunities, and future directions in the indian pharmaceutical market

This study explores the key obstacles to the adoption of GLP-1 receptor agonists in India, focusing on economic, cultural, and healthcare infrastructure barriers. Economically, GLP-1 receptor agonists are significantly more expensive than traditional antidiabetic medications, which poses a major barrier, particularly for the substantial portion of the Indian population living below the poverty line and the prevalence of out-of-pocket healthcare expenditure. Additionally, the absence of generic versions keeps prices high and limits accessibility. Culturally, Indian patients generally prefer oral medications over injectables, and the injectable nature of GLP-1 receptor agonists deters acceptance due to fear of needles and associated discomfort. Furthermore, many patients rely on traditional medicine practices like Ayurveda and homeopathy, leading to resistance against newer, scientifically advanced treatments. In terms of healthcare infrastructure, rural areas often lack adequate healthcare facilities and specialists who can prescribe and manage GLP-1 receptor agonist therapy, and inadequate infrastructure for cold chain storage affects the availability and stability of these medications. The shortage of endocrinologists and diabetes specialists, especially in rural and semi-urban areas, further results in inadequate guidance and management of complex therapies. This analysis underscores the multifaceted challenges hindering the adoption of GLP-1 receptor agonists in India and emphasizes the need for comprehensive strategies to address these economic, cultural, and infrastructural barriers.